1、Focused on Growing our Most Valuable Asset Zealand PharmaAnnual Report2021Company reg.no.20045078TodayAnnual General Meeting 2021#WithZealContentsCEO Letter Read more on page 5Other supplementary reports 2021 Corporate Social Responsibility Report Remuneration Report Corporate Governance ReportSee o
2、ur pipeline Read more on page 19OverviewZealand Pharma in short 4Letter from the CEO and the Chairman 52021 Achievements 8Consolidated key figures 92022 Outlook and Objectives 10Zealand Pharmas USlaunchZealand Pharmas first independent launch 12Five in 25 13Zealand Pharmas R&D platform and pipelineP
3、eptide platform 15Zealand Pharma pipeline 19Severe Hypoglycemia in diabetes/Zegalouge 20Congenital Hyperinsulinism(CHI)21Type 1 diabetes 22Obesity/Type 2 diabetes 23Short Bowel Syndrome(SBS)24Corporate mattersCorporate Matters 26Corporate Social Responsibility 29Our People and Culture 31Risk managem
4、ent and internal control 33Financial review 36Shareholder information 39Board of Directors 41Corporate Management 44Financial statementsManagement reviewFollow usConsolidated financial statementsIncome statement 48Statement of comprehensive income 48Statement of financial position 49Statement of cas
5、h flows 50Statement of changes in equity 50Business overview 51Notes 52Financial statements of the parent companyIncome statement 96Statement of comprehensive income 96Statement of financial position 97Statement of cash flows 98Statement of changes in equity 98Notes 99Alternative performance measure
6、s for the group(non-audited)113Reports Statement of the Board of Directors and Executive Management 114Independent auditors report 115Other informationSources 121Company information 1212Zealand Pharma Annual Report 2021OverviewZealand Pharma in short 4Letter from the CEO and the Chairman 52021 Achie